MOUSA BOTROS: Open Payments
NPI 1508248881 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$834 in 34 payments from 6 companies in 2025. Trend: 2023 $25 · 2024 $351 · 2025 $834
Food & beverage: $834
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $287 |
| Luye Pharma (USA) Ltd. | 6 | $154 |
| Janssen Pharmaceuticals, Inc | 7 | $148 |
| Alkermes, Inc. | 5 | $126 |
| Otsuka America Pharmaceutical, Inc. | 3 | $78 |
| E.R. Squibb & Sons, L.L.C. | 2 | $42 |
Products named: UZEDY, ERZOFRI EXTENDED-RELEASE, INVEGA SUSTENNA, ARISTADA, AUSTEDO XR, ABILIFY MAINTENA, COBENFY, ABILIFY ASIMTUFII.
Industry payments across FL — which companies pay providers there.
